caa a22 4500 445295147 CHVBK 20180317142539.0 cr unu---uuuuu 170323e20101201xx s 000 0 eng 10.1007/s11657-010-0035-7 doi (NATIONALLICENCE)springer-10.1007/s11657-010-0035-7 Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications [Elektronische Daten] [Nick Freemantle, Cyrus Cooper, Christian Roux, Adolfo Díez-Pérez, Francis Guillemin, Bengt Jonsson, Sergio Ortolani, Johannes Pfeilschifter, Rob Horne, Shilpa Kakad, Susan Shepherd, Gerd Möller, Anne Marciniak, Luc Martinez] Summary: Prospective Observational Scientific Study Investigating Bone Loss Experience in Europe (POSSIBLE EU®) is an ongoing longitudinal cohort study that utilises physician- and patient-reported measures to describe the characteristics and management of postmenopausal women on bone loss therapies. We report the study design and baseline characteristics of 3,402 women recruited from general practice across five European countries. Purpose: The POSSIBLE EU® is a study describing the characteristics and management of postmenopausal women receiving bone loss medications. Methods: Between 2005 and 2008, general practitioners enrolled postmenopausal women initiating, switching or continuing treatment with bone loss treatment in France, Germany, Italy, Spain and the UK. Patients and physicians completed questionnaires at study entry and at 3-month intervals, for 1year. Results: Of 3,402 women enrolled (mean age 68.2years [SD] 9.83), 96% were diagnosed with low bone mass; 55% of these using dual energy X-ray absorptiometry. Most women (92%) had comorbidities. Mean minimum T score (hip or spine) at diagnosis was −2.7 (SD 0.89; median −2.7 [interquartile range, −3.2, −2.2]) indicating low bone mineral density. Almost 40% of the women had prior fractures in adulthood, mostly non-vertebral, non-hip in nature, 30% of whom had at least two fractures and more than half experienced moderate/severe pain or fatigue. Bisphosphonates were the most common type of bone loss treatment prescribed in the 12months preceding the study. Conclusions: POSSIBLE EU® characterises postmenopausal women with low bone mass, exhibiting a high rate of prevalent fracture, substantial bone fragility and overall comorbidity burden. Clinical strategies for managing osteoporosis in this population varied across the five participating European countries, reflecting their different guidelines, regulations and standards of care. The Author(s), 2010 Cohort studies nationallicence Osteoporosis nationallicence Postmenopausal osteoporosis nationallicence Prospective studies nationallicence Freemantle Nick Clinical Epidemiology & Biostatistics, School of Health and Population Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK aut Cooper Cyrus MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK aut Roux Christian Cochin Hospital, Department of Rheumatology, Paris Descartes University, Paris, France aut Díez-Pérez Adolfo Dept. de Medicina, Hospital del Mar IMIM-UAB-RETICEF, Barcelona, Spain aut Guillemin Francis Nancy-University, EA 4003, Vandoeuvre-les Nancy, France aut Jonsson Bengt Stockholm School of Economics, Stockholm, Sweden aut Ortolani Sergio Istituto Auxologico Italiano, Milan, Italy aut Pfeilschifter Johannes Klinik für Innere Medizin III, Alfried Krupp Krankenhaus, Essen, Germany aut Horne Rob Centre for Behavioural Medicine, The School of Pharmacy, University of London, London, UK aut Kakad Shilpa Clinical Research, Amgen Ltd, Uxbridge, UK aut Shepherd Susan Biostatistics, Amgen Ltd, Uxbridge, UK aut Möller Gerd International Development, Amgen (Europe) GmbH, Zug, Switzerland aut Marciniak Anne Health Economics, Amgen Ltd, Uxbridge, UK aut Martinez Luc Société Française de Médecine Générale, Issy les Moulineaux, France aut Archives of Osteoporosis Springer-Verlag 5/1-2(2010-12-01), 61-72 1862-3522 5:1-2<61 2010 5 11657 https://doi.org/10.1007/s11657-010-0035-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11657-010-0035-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Freemantle Nick Clinical Epidemiology & Biostatistics, School of Health and Population Sciences, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK aut NATIONALLICENCE 700 1- Cooper Cyrus MRC Epidemiology Resource Centre, University of Southampton, Southampton, UK aut NATIONALLICENCE 700 1- Roux Christian Cochin Hospital, Department of Rheumatology, Paris Descartes University, Paris, France aut NATIONALLICENCE 700 1- Díez-Pérez Adolfo Dept. de Medicina, Hospital del Mar IMIM-UAB-RETICEF, Barcelona, Spain aut NATIONALLICENCE 700 1- Guillemin Francis Nancy-University, EA 4003, Vandoeuvre-les Nancy, France aut NATIONALLICENCE 700 1- Jonsson Bengt Stockholm School of Economics, Stockholm, Sweden aut NATIONALLICENCE 700 1- Ortolani Sergio Istituto Auxologico Italiano, Milan, Italy aut NATIONALLICENCE 700 1- Pfeilschifter Johannes Klinik für Innere Medizin III, Alfried Krupp Krankenhaus, Essen, Germany aut NATIONALLICENCE 700 1- Horne Rob Centre for Behavioural Medicine, The School of Pharmacy, University of London, London, UK aut NATIONALLICENCE 700 1- Kakad Shilpa Clinical Research, Amgen Ltd, Uxbridge, UK aut NATIONALLICENCE 700 1- Shepherd Susan Biostatistics, Amgen Ltd, Uxbridge, UK aut NATIONALLICENCE 700 1- Möller Gerd International Development, Amgen (Europe) GmbH, Zug, Switzerland aut NATIONALLICENCE 700 1- Marciniak Anne Health Economics, Amgen Ltd, Uxbridge, UK aut NATIONALLICENCE 700 1- Martinez Luc Société Française de Médecine Générale, Issy les Moulineaux, France aut NATIONALLICENCE 773 0- Archives of Osteoporosis Springer-Verlag 5/1-2(2010-12-01), 61-72 1862-3522 5:1-2<61 2010 5 11657 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer